Evidence map›Paper›PMID 38191781›Full record

ArticleDrug delivery and translational research2024

pH and redox dual response nano-suppository for the treatment of ulcerative colitis.

Yijun Wu, Jinfeng Song, Xiaochen Wang, Longxia Li, Jie Chang, Yunfeng Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yijun Wu *College of Pharmacy of Henan University, Kaifeng, 475004, Henan, China.
Jinfeng Song *College of Pharmacy of Henan University, Kaifeng, 475004, Henan, China.
Xiaochen WangCollege of Pharmacy of Henan University, Kaifeng, 475004, Henan, China.
Longxia LiCollege of Pharmacy of Henan University, Kaifeng, 475004, Henan, China.
Jie ChangZhengzhou Taifeng Pharmaceutical Co., Ltd, Zhengzhou, 450000, Henan, China.
Yunfeng MaInstitute of Microbial Engineering, Laboratory of Bioresource and Applied Microbiology, School of Life Sciences, Henan University, Kaifeng, 475004, China. mayunfenghenu@163.com.
Henan University · CNHenan Energy & Chemical Industry Group (China) · CN

Funding

The Education Department of Henan Province 23A350008
6 · The paper itself

Abstract

To improve treatment compliance and reach sustained and controlled drug release in the colon, we developed a hollow mesoporous silica nano-suppository that responded to both pH and redox stimuli. Firstly, we prepared hollow mesoporous silica nanoparticles containing disulfide bonds (HMSN-SS) and loaded them with 5-ASA. Secondly, we modified the surface of HMSN-SS with polydopamine (PDA) and chitosan (CS) and molded the suppository, which we named 5-ASA@HMSN-SS-PDA-CS (5-ASA@HSPC). By administering 5-ASA@HSPC rectally, it acted directly on the affected area. CS helped the nanoparticles adhere to the colon's surface, while PDA dissociates from HMSN-SS due to protonation in the acidic environment of the ulcerative colon. The disulfide bonds were destroyed by the reducing environment of the colon, leading to a stable and slow release of encapsulated 5-ASA from the pores of HMSN. Finally, in vitro release experiments and in vivo pharmacokinetic and pharmacodynamic experiments had demonstrated that 5-ASA@HSPC exhibited a slow and steady action at the colonic site, with an excellent safety profile. This novel approach showed great potential in the treatment of ulcerative colitis.

Indexed as

Colitis, UlcerativeMesalamineSuppositoriesAnimalsAnimals, Outbred StrainsBiocompatible MaterialsChitosanDrug CarriersDrug CompoundingHumansHydrogen-Ion ConcentrationIndolesMaleMiceMice, Inbred C57BLNanoparticlesBiocompatible MaterialsChitosanDrug CarriersIndolesMesalaminepolydopaminePolymersSilicon DioxideSuppositoriesHollow mesoporous silica nanoparticlespH-responsive releaseRedox-triggered releaseUlcerative colitis therapy

Identifiers

PMID38191781
OpenAlexW4390675592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.